3-(4-fluorophenyl)-5-(thiophen-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide | 1019177-86-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(4-fluorophenyl)-5-(thiophen-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
• 英文别名: 5-(4-fluorophenyl)-3-thiophen-2-yl-3,4-dihydropyrazole-2-carbothioamide
• CAS: 1019177-86-6
• 化学式: C₁₄H₁₂FN₃S₂
• 分子量: 305.4
• InChiKey: MFIIBVJFPXSJJX-UHFFFAOYSA-N

物化性质

• 熔点：
  203-205 °C
• 沸点：
  454.5±55.0 °C(Predicted)
• 密度：
  1.44±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  102
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(4-fluorophenyl)-5-(thiophen-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide 、 2-溴-4'-(三氟甲基)苯乙酮 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 以52%的产率得到2-(3-(4-fluorophenyl)-5-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl)-4-(4-(trifluoromethyl)phenyl)thiazole
  参考文献：
  名称：

  Synthesis, biological evaluation and 3D-QSAR study of novel 4,5-dihydro-1H-pyrazole thiazole derivatives as BRAFV600E inhibitors

  摘要：

  Many reports implied that the BRAF serine/threonine kinase was mutated in various types of human tumors, which were related with cell growth, survival and differentiation. To provide new therapeutic opportunities, a series of novel 4,5-dihydro-1H-pyrazole derivatives (6a-10d) containing thiazole moiety as potential V600E mutant BRAF kinase (BRAF(V600E)) inhibitors were designed and synthesized. All compounds were evaluated in vitro for anticancer activities against WM266.4 human melanoma cell line and breast cancer MCF-7 cell line. Compound 10d displayed the most potential antiproliferative activity with an IC50 value of 0.12μM against cell line WM266.4 and 0.16μM against MCF-7 with positive control Sorafenib. Results of the inhibitory activity against BRAF(V600E) revealed that compound 10d was bearing the best bioactivity with IC50 of 0.05μM as well. On the basis of the result of flow cytometry, with the dose of compound 10d increasing, more and more cancer cell gradually encountered apoptosis or died, which indicated the compound 10d could induce remarkable apoptosis of MCF-7 and WM266.4 cells in a dose dependent manner. Furthermore, docking simulation of inhibitor analogues and 3D-QSAR modeling provided potential binding model and further knowledge of pharmacophore.

  DOI：

  10.1016/j.bmc.2014.11.029
• 作为产物：
  描述：

  4-氟苯乙酮 在 potassium hydroxide 作用下， 以 乙醇 为溶剂， 反应 0.17h， 生成 3-(4-fluorophenyl)-5-(thiophen-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
  参考文献：
  名称：

  新型 1-(4-取代-噻唑-2-基)-3,5-二(杂)芳基-吡唑啉衍生物的合成和对人COX-1的选择性抑制活性

  摘要：

  3,5-二(杂)芳基-1-硫代氨基甲酰基-2-反应得到新型1-(4-乙基羧酸酯-噻唑-2-基)-3,5-二(杂)芳基-2-吡唑啉衍生物吡唑啉与α-溴-丙酮酸乙酯。合成的化合物通过光谱数据得到证实，并进行了分析，以评估它们在体外抑制人类环氧合酶 (hCOX) 两种异构体的能力。一些衍生物（化合物 5、6、13、16 和 17）在微摩尔范围内对 hCOX-1 显示出有希望的选择性，并且显示出与参考药物（吲哚美辛、双氯芬酸）相似或更好的选择性指数。在（4-取代-噻唑-2-基）吡唑啉衍生物的 C3 上与 4-取代苯基或杂芳基相连的 C5 上引入苯基或 4-F-苯环提高了对 hCOX-的活性1.

  DOI：

  10.1002/ardp.201200249

文献信息

• Synthesis and Selective Inhibitory Activity Against Human COX-1 of Novel 1-(4-Substituted-thiazol-2-yl)-3,5-di(hetero)aryl-pyrazoline Derivatives
  作者：Simone Carradori、Daniela Secci、Adriana Bolasco、Celeste De Monte、Matilde Yáñez

  DOI：10.1002/ardp.201200249

  日期：2012.12

  (compounds 5, 6, 13, 16, and 17) displayed promising selectivity against hCOX‐1 in the micromolar range and were shown to have a selectivity index similar or better than the reference drugs (indometacin, diclofenac). The introduction of a phenyl or a 4‐F‐phenyl ring on the C5 associated with a 4‐substituted phenyl or a heteroaryl group on the C3 of (4‐substituted‐thiazol‐2‐yl)pyrazoline derivatives improved

  3,5-二(杂)芳基-1-硫代氨基甲酰基-2-反应得到新型1-(4-乙基羧酸酯-噻唑-2-基)-3,5-二(杂)芳基-2-吡唑啉衍生物吡唑啉与α-溴-丙酮酸乙酯。合成的化合物通过光谱数据得到证实，并进行了分析，以评估它们在体外抑制人类环氧合酶 (hCOX) 两种异构体的能力。一些衍生物（化合物 5、6、13、16 和 17）在微摩尔范围内对 hCOX-1 显示出有希望的选择性，并且显示出与参考药物（吲哚美辛、双氯芬酸）相似或更好的选择性指数。在（4-取代-噻唑-2-基）吡唑啉衍生物的 C3 上与 4-取代苯基或杂芳基相连的 C5 上引入苯基或 4-F-苯环提高了对 hCOX-的活性1.
• Discovery and modification of sulfur-containing heterocyclic pyrazoline derivatives as potential novel class of β-ketoacyl-acyl carrier protein synthase III (FabH) inhibitors
  作者：Yu-Shun Yang、Fei Zhang、Chao Gao、Yan-Bin Zhang、Xiao-Liang Wang、Jian-Feng Tang、Jian Sun、Hai-Bin Gong、Hai-Liang Zhu

  DOI：10.1016/j.bmcl.2012.05.091

  日期：2012.7

  A series of sulfur-containing heterocyclic pyrazoline derivatives (C1-C18; D1-D9) have been synthesized and purified (all are new except one) to be screened for FabH inhibitory activity. Compound C14 showed the most potent biological activity against Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus and Bacillus subtilis (MIC values: 1.56-3.13 mu g/mL), being comparable with the positive control, while D6 performed the best in the thiazolidinone series (MIC values: 3.13-6.25 mu g/mL). They also demonstrated strong broad-spectrum antimicrobial activity. Compounds C14 and D6 exhibited the most potent E. coli FabH inhibitory activity with IC50 of 4.6 and 8.4 mu M, respectively, comparable with the positive control DDCP (IC50 = 2.8 mu M). Docking simulation was performed to position compound C14 and D6 into the E. coli FabH structure active site to determine the probable binding model. The structurally modification of previous compounds and the attempt in innovative target have brought a positive progress. (C) 2012 Published by Elsevier Ltd.
• Synthesis and inhibitory activity against human monoamine oxidase of N1-thiocarbamoyl-3,5-di(hetero)aryl-4,5-dihydro-(1 H )-pyrazole derivatives
  作者：Franco Chimenti、Simone Carradori、Daniela Secci、Adriana Bolasco、Bruna Bizzarri、Paola Chimenti、Arianna Granese、Matilde Yáñez、Francisco Orallo

  DOI：10.1016/j.ejmech.2009.11.003

  日期：2010.2

  A series of N1-thiocarbamoyl-3,5-di(hetero)aryl-4,5-dihydro-(1H)-pyrazole derivatives has been synthesized and assayed for their ability to inhibit the activity of the A and B isoforms of human monoamine oxidase (hMAO). Some of these compounds were endowed with a selective inhibitory activity against hMAO-B in the micromolar range. The most active of the series is the compound 13, N1-thiocarbamoyl-3-(fur-2'-yl)-5-(4'-fluoro-phenyl)-4,5-dihydro-(1H)-pyrazole, with IC50 2.75 +/- 0.81 mu M value and selectivity ratio of 25, which is the best candidate for further investigations. (C) 2009 Elsevier Masson SAS. All rights reserved.
• Synthesis, biological evaluation and 3D-QSAR study of novel 4,5-dihydro-1H-pyrazole thiazole derivatives as BRAFV600E inhibitors
  作者：Meng-Yue Zhao、Yong Yin、Xiao-Wei Yu、Chetan B. Sangani、Shu-Fu Wang、Ai-Min Lu、Li-Fang Yang、Peng-Cheng Lv、Ming-Guo Jiang、Hai-Liang Zhu

  DOI：10.1016/j.bmc.2014.11.029

  日期：2015.1

  Many reports implied that the BRAF serine/threonine kinase was mutated in various types of human tumors, which were related with cell growth, survival and differentiation. To provide new therapeutic opportunities, a series of novel 4,5-dihydro-1H-pyrazole derivatives (6a-10d) containing thiazole moiety as potential V600E mutant BRAF kinase (BRAF(V600E)) inhibitors were designed and synthesized. All compounds were evaluated in vitro for anticancer activities against WM266.4 human melanoma cell line and breast cancer MCF-7 cell line. Compound 10d displayed the most potential antiproliferative activity with an IC50 value of 0.12μM against cell line WM266.4 and 0.16μM against MCF-7 with positive control Sorafenib. Results of the inhibitory activity against BRAF(V600E) revealed that compound 10d was bearing the best bioactivity with IC50 of 0.05μM as well. On the basis of the result of flow cytometry, with the dose of compound 10d increasing, more and more cancer cell gradually encountered apoptosis or died, which indicated the compound 10d could induce remarkable apoptosis of MCF-7 and WM266.4 cells in a dose dependent manner. Furthermore, docking simulation of inhibitor analogues and 3D-QSAR modeling provided potential binding model and further knowledge of pharmacophore.